{"disease":{"id":"melanoma-stage-iiib-ivm1a","name":"melanoma stage iiib ivm1a"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03972046","title":"Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"TriHealth Inc.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}